Position paper: Neurinox achievements and why more research on neuroinflammation is needed

NEURINOX, a 5-year international biomedical FP7 European Commission research project is ending on 31 December 2016. Continuing large scale collaborative research is therefore required to find possible treatment for affected patients. We have hence issued a Position Paper with an overview of what has been achieved in NEURINOX and the fields where we need a continued research effort to bring the NEURINOX findings closer to clinical application.

© NEURINOX Consortium, 2016

NEURINOX scientists have investigated how novel treatments can be created on the basis of these observations. They developed the first generation of molecules with drug-like characteristics acting at the source of oxygen radicals – enzymes called NADPH oxidases (NOX). These pharmacological tools are now available for preclinical tests and will give rise to future therapeutics. Furthermore, a number of prospective clinical studies involving multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) patients led to discovery of new biomarkers. These findings are encouraging, and their relevance to other neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, chronic inflammatory peripheral neurites, and Huntington’s disease should be tested in the future.

If you need any additional information, please do not hesitate to contact the Project Scientific Manager, Vincent Jaquet. You will find all his contact details in the following link:
http://www.neurinox.eu/media/NEURINOX_Position_Paper_Neuroinflammation_R1.pdf

Keywords

NOX, Neuroinflammation, neurodegenerative disease, ALS, MS, ROS, Epilepsy, Parkinson, biomarkers, brain dysfunctionality, drug development, genomics, proteomics, Alzheimer

Countries

Switzerland